“It’s not just about slowing aging down or stopping it, it’s about bringing yourself back to a younger biological age, which is effectively age reversal.”
Daniel Ives, founder of Shift Bioscience, introduces their transcriptomic driver clock which enables them to identify putative drug targets for safer cellular rejuvenation, which might avoid the challenges coupled to therapeutic use of Yamanaka factors. Daniel goes into detail on what the clock enables, how they are planning to validate these putative targets, his wishlist for tools that could help speed up and de-risk longevity and aging focused drug development.
Music:
I Knew a Guy by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/
Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1100199
Artist: http://incompetech.com/
Remarks: The length of this recording has been altered.
Session Summary: Drug Target Discovery for Cellular Rejuvenation by ‘Driver’ Clocks | Daniel Ives, Shift Bioscience - Foresight Institute
The Foresight Institute is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.
Allison Duettmann is the president and CEO of Foresight Institute. She directs the Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs, Fellowships, Prizes, and Tech Trees, and shares this work with the public. She founded Existentialhope.com, co-edited Superintelligence: Coordination & Strategy, co-authored Gaming the Future, and co-initiated The Longevity Prize.
Apply to Foresight’s virtual salons and in person workshops here!
We are entirely funded by your donations. If you enjoy what we do please consider donating through our donation page.
Visit our website for more content, or join us here:
","author_name":"Foresight Institute"}